Exenatide Compared with Twice-Daily Biphasic Insulin Aspart in Patients with Type 2 Diabetes Using Sulfonylurea and Metformin

Study identifier:H8O-MC-GWAD

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

Efficacy of Exenatide (AC2993, Synthetic Exendin-4, LY2148568) Compared with Twice-Daily Biphasic Insulin Aspart in Patients with Type 2 Diabetes Using Sulfonylurea and Metformin

Medical condition

Diabetes Mellitus, Type 2

Phase

Phase 3

Healthy volunteers

No

Study drug

exenatide, biphasic insulin aspart

Sex

All

Actual Enrollment

505

Study type

Interventional

Age

30 Years - 75 Years

Date

Study Start Date: 01 Nov 2003
Primary Completion Date: 01 Jul 2008
Study Completion Date: 01 Jul 2008

Study design

Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment

Verification:

Verified 01 Mar 2015 by AstraZeneca Pharmaceuticals

Sponsors

AstraZeneca Pharmaceuticals

Collaborators

Eli Lilly and Company

Inclusion and exclusion criteria